BioNTech

Primarily focused on developing individualized cancer therapy, BioNTech is a biotechnology company located in Mainz, Germany.

Approach

Their method revolves around several platforms in medicine; mRNA Therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. Coupled with their approach to patient specific needs, they have seen success in providing unique treatments.

Sequencing patient's tumor
Mapping of mutations
Bioinformatic algorithms
Selection of neoepitopes

Pipeline

COVID-19

BNT162 is BioNTech’s mRNA vaccine program aimed at preventing COVID-19 infection. It is the first product candidate from Project Lightspeed and leverages BioNTech’s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production, and its global clinical development capabilities, drawing on BioNTech’s network of global collaborators. BioNTech is partnered with Pfizer for co-development and distribution of BNT162 and with Fosun Pharma on the vaccine development in China.

Timeline

November 25, 2020

BioNTech and Shanghai Fosun Pharmaceutical says they will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.

November 12, 2020

Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

The European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.

September 15, 2020

BioNTech raises a $455,600,000 grant.

June 29, 2020

BioNTech raises a $250,000,000 venture round from Temasek Holdings.

December 17, 2019

BioNTech raises a $60,747,000 venture round from European Investment Bank.

September 4, 2019

BioNTech raises a $55,000,000 grant from Bill & Melinda Gates Foundation.

July 9, 2019

BioNTech raises a $325,000,000 series B round.

January 4, 2018

BioNTech raises a $91,500,000 private equity.

January 3, 2017

BioNTech raises a $270,000,000 series A round.

2009

BioNTech was founded by Christoph Huber and Ugur Sahin.

Funding Rounds

Acquisitions

Patents

Further Resources

Title

Author

Link

Type

Date

BioNTech Corporate Video

https://youtu.be/-7QOo7LXsp0

News

Title

Author

Date

Publisher

Description

The Latest: Court rejects challenge to Maine shot mandate

By The Associated Press

October 15, 2021

AP NEWS

PORTLAND, Maine -- A federal appeals court has denied an emergency request to stop a COVID-19 vaccine mandate from going into effect in Maine.The rule, announced by Democratic Gov. Janet Mills, requires health care workers to get vaccinated against the disease by Oct.

BioNTech looks beyond Pfizer COVID-19 shot with an mRNA vaccine for colorectal cancer

Kyle LaHucik

September 30, 2021

FierceBiotech

What will BioNTech do after helping Pfizer make a COVID-19 vaccine that has been delivered to hundreds of millions of people worldwide? Biotech insiders and the general public alike now have an answer: A phase 2 study of a different mRNA in a vaccine for colorectal cancer.

For BioNTech, the COVID-19 vaccine was simply the opening act

Darrell Etherington

September 21, 2021

TechCrunch

Ultimately, BioNTech's mission is to make treatments that are optimized not only to specific patient needs, but also to time and place.

BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma

Arlene Weintraub

September 8, 2021

FierceBiotech

A BioNTech-led team designed a cocktail of mRNAs that instruct cells to produce four cancer-fighting molecules. The treatment suppressed tumors in mouse models of colon cancer and melanoma, and it worked even better when combined with checkpoint inhibiting drugs, they reported in a new study.

The mRNA era has arrived thanks to COVID-19. What's next in the pipeline?

Annalee Armstrong

August 31, 2021

FierceBiotech

COVID-19 wasn't even in the picture when mRNA was developed, but with the regulatory runway cleared, biotechs that have been working on the tech for years are ready for liftoff. Yes, Moderna and BioNTech are the rock stars in the business--launched to household name status with the COVID-19 vaccines at the end of 2020. But there's more to the pipeline than just these headliners.

Timeline

Funding Rounds

Acquisitions

Patents

Further Resources

News

References

Company attributes

Other attributes

Categories

Related Topics

Contributors